Agenus Has Two Separate Press Releases
In the First Press Release from Agenus:
Agenus (AGEN) announced that it will be making a scientific presentation today on optimal anti-cancer combinations with Fc enhanced anti-CTLA-4, AGEN1181 at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting.
AGEN1181 - an Fc-engineered anti-CTLA-4 that has . . .